NCT02300922 (RITCOLON) is a Phase 1, PHASE2 clinical trial of Antibody TF2 in Metastatic Colorectal Cancer, sponsored by Nantes University Hospital.

Who is sponsoring NCT02300922?

NCT02300922 is sponsored by Nantes University Hospital.

What drugs are being tested in NCT02300922?

Interventions in NCT02300922: Antibody TF2, 90-Y-IMP-288, 111-In-IMP-288.

What condition does NCT02300922 study?

NCT02300922 studies Metastatic Colorectal Cancer.

Is NCT02300922 still recruiting?

NCT02300922 is currently terminated. Last updated 1 August 2022.

Last reviewed 2022-08-01 · How we verify

NCT02300922: RITCOLON

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer

Terminated Phase 1, PHASE2 Last updated 1 August 2022

What this trial tests

Phase 1, PHASE2 trial testing Antibody TF2 in Metastatic Colorectal Cancer in 7 participants. Terminated before completion.

Timeline

27 January 2015

Primary endpoint
20 September 2017

20 December 2017

Quick facts

Lead sponsor	Nantes University Hospital
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	7
Start date	27 January 2015
Primary completion	20 September 2017
Estimated completion	20 December 2017
Sites	1 location across France

Drugs / interventions tested

Antibody TF2 — full drug profile →
90-Y-IMP-288 — full drug profile →
111-In-IMP-288 — full drug profile →

Conditions studied

Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Metastatic Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase I/II, Open-labeled, Prospective, Multi-center study of a Pretargeted Radioimmunotherapy in metastatic colorectal cancer with ractionated injections of TF2 plus 90Y-IMP288 (RITCOLON).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances and challenges of bispecific antibodies in solid tumors.
Wu Y, Yi M, Zhu S, Wang H, et al · · 2021 · cited 64× · PMID 34922633 · DOI 10.1186/s40164-021-00250-1
Pretargeting: A Path Forward for Radioimmunotherapy.
Cheal SM, Chung SK, Vaughn BA, Cheung NV, et al · · 2022 · cited 54× · PMID 36215514 · DOI 10.2967/jnumed.121.262186
Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy.
Jallinoja VIJ, Houghton JL. · · 2021 · cited 25× · PMID 34016727 · DOI 10.2967/jnumed.120.260687
New Approaches in Radiotherapy.
Webster M, Podgorsak A, Li F, Zhou Y, et al · · 2025 · cited 9× · PMID 40563630 · DOI 10.3390/cancers17121980
Short Linear Motifs in Colorectal Cancer Interactome and Tumorigenesis.
Fasano C, Grossi V, Forte G, Simone C. · · 2022 · cited 5× · PMID 36496998 · DOI 10.3390/cells11233739

Verify or expand the search:

Other recruiting trials for Metastatic Colorectal Cancer

Currently open trials in the same condition.

NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting

Other Nantes University Hospital trials

Trials by the same sponsor.

NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02300922 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
Last refreshed: 1 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02300922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing